Drug profile · INN
indacaterol maleate
ARCAPTA NEOHALER
indacaterol maleate (ARCAPTA NEOHALER) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — indacaterol maleate
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
indacaterol maleate (ARCAPTA NEOHALER) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is indacaterol maleate?
indacaterol maleate (ARCAPTA NEOHALER) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for indacaterol maleate?
ARCAPTA NEOHALER is a marketed brand name for indacaterol maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of indacaterol maleate?
indacaterol maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.